SCHEMBL196629

SCHEMBL196629

CC(C)(C)Oc1ccc(C(C)(C)c2ccc(OC(C)(C)C)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.46
ESR1 P03372 4/20 0.46
TSHR P16473 3/20 0.46
ESR2 Q92731 3/20 0.46
CYP3A4 P08684 2/20 0.46
SLC6A2 P23975 2/20 0.46
SLC6A4 P31645 2/20 0.46
SLC6A3 Q01959 2/20 0.46
AR P10275 2/20 0.46
HTR6 P50406 1/20 0.46
ESRRG P62508 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ALDH1A1 P00352 5/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
MAPT P10636 3/20 0.42
TP53 P04637 2/20 0.42
HIF1A Q16665 2/20 0.42
CYP1A2 P05177 1/20 0.42
PPARG P37231 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16281926 0.93 MAPT (0.47) HPGDESR1TSHRESR2CYP3A4
SCHEMBL15869161 0.93 HPGD (0.41) HPGDESR1TSHRESR2CYP3A4
SCHEMBL14134700 0.91 CA1 (0.48) HPGDESR1TSHRESR2CYP3A4
SCHEMBL18715597 0.91 TSHR (0.46) HPGDESR1TSHRESR2CYP3A4
SCHEMBL12204980 0.89 ESR2 (0.67) HPGDESR1TSHRESR2CYP3A4
SCHEMBL26746 0.86 SLC6A2 (0.44) HPGDTSHRCYP3A4SLC6A2SLC6A4
SCHEMBL24973109 0.85 MEN1 (0.39) HPGDESR1TSHRESR2CYP3A4
SCHEMBL13946248 0.85 MEN1 (0.39) HPGDESR1TSHRESR2CYP3A4
SCHEMBL13066123 0.85 PTPN5 (0.41) HPGDESR1TSHRESR2CYP3A4
SCHEMBL13485133 0.85 NQO1 (0.54) HPGDTSHRARALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1308782-B1 Chemically amplified positive resist composition and patterning process SHINETSU CHEMICAL CO (JP) 2012-09-05 EP claimed
US-6660447-B2 Copolymers of fluorinated vinyl phenol units and acrylonitrile units has high transmittance to VUV radiation SHIN-ETSU CHEMICAL CO., LTD. (JP) 2003-12-09 US claimed
US-12016856-B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders ARDELYX, INC. (US) 2024-06-25 US disclosed
US-20240067777-A1 CURABLE COMPOUND PRODUCT DAICEL CORPORATION (JP) 2024-02-29 US disclosed
US-11318129-B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders ARDELYX, INC. (US) 2022-05-03 US disclosed
US-11242337-B2 Compounds useful for treating gastrointestinal tract disorders ARDELYX, INC. (US) 2022-02-08 US disclosed
US-11147884-B2 Inhibitors of NHE-mediated antiport ARDELYX, INC. (US) 2021-10-19 US disclosed
US-11027242-B2 Nanofiltration membranes and methods of use NOVOMER, INC. (US) 2021-06-08 US disclosed
US-20210095122-A1 THERMALLY-REARRANGED POLYMER BLENDS FOR GAS SEPARATION MEMBRANES UNITED STATES DEPARTMENT OF ENERGY 2021-04-01 US disclosed
US-10940146-B2 NHE3-binding compounds and methods for inhibiting phosphate transport ARDELYX, INC. (US) 2021-03-09 US disclosed
US-10890498-B2 Sensor for a physical feature, preferably comprising a multilayer structure UNIVERSITE DE BRETAGNE SUD (FR) 2021-01-12 US disclosed
EP-0875787-A1 Method for reducing the substrate dependence of resist Wako Pure Chemical Industries, Ltd. (JP) 1998-11-04 EP disclosed
US-5780206-A USING AN ANTHRACENE DERIVATIVE AS AN ABSORBER ON HIGHLY REFLECTIVE SURFACES; ALKALI-SOLUBLE POLYMERS; GENERATION OF ACID CATALYSTS; FINE PATTERNS WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1998-07-14 US disclosed
US-5741628-A CHEMICAL AMPLIFICATION WHICH GENERATES AN ACID IN RESPONSE TO LASER RADIATION MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1998-04-21 US disclosed
US-5695910-A RESIN BECOMES ALKALI SOLUBLE BY ELIMINATING PROTECTIVE GROUPS BY ACTION OF IN SITU GENERATED ACID WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1997-12-09 US disclosed
US-5679500-A FORMING RESIST FILM BY USING A CHEMICAL AMPLIFICATION RESIST WHICH GENERATES AN ACID IN RESPONSE TO LASER LIGHT AND WHICH REACTS WITH THE ACID MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1997-10-21 US disclosed
US-5658711-A FORMING RESIST FILM CONTAINING BASE GENERATOR, GENERATING BASE BY RADIATION, FORMING METAL OXIDE FILM, ETCHING MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1997-08-19 US disclosed
EP-0691674-A2 Method of forming micropatterns MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1996-01-10 EP disclosed
EP-0675410-A1 Resist composition for deep ultraviolet light WAKO PURE CHEMICAL INDUSTRIES LTD (JP) 1995-10-04 EP disclosed
EP-0595361-A2 Method of forming micropatterns MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1994-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11242337-B2 Compounds useful for treating gastrointestinal tract disorders SLC10A2, FABP2, SLC10A1 HPGD 149/4885ESR1 4149/4885TSHR 579/4885
US-11027242-B2 Nanofiltration membranes and methods of use MLEC, EPCAM, LNPK HPGD 2068/4885ESR1 3897/4885TSHR 2938/4885
US-11318129-B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders SLC10A1, SLC10A2, FABP3 HPGD 392/4885ESR1 2899/4885TSHR 680/4885
US-10940146-B2 NHE3-binding compounds and methods for inhibiting phosphate transport SLC34A3, SLC34A2, SLC34A1 HPGD 1068/4885ESR1 4386/4885TSHR 3112/4885
US-11147884-B2 Inhibitors of NHE-mediated antiport SLC10A1, SLC10A2, SLC9A2 HPGD 384/4885ESR1 3345/4885TSHR 681/4885
US-12016856-B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders SLC10A1, SLC10A2, FABP3 HPGD 392/4885ESR1 2899/4885TSHR 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.